Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B′ strains by recombinant Mycobacterium bovis BCG-based candidate vaccine

被引：23

作者：

Chujoh, Y

Matsuo, K

Yoshizaki, H

Nakasatomi, T

Someya, K

Okamoto, Y

Naganawa, S

Haga, S

Yoshikura, H

Yamazaki, A

Yamazaki, S

Honda, M

机构：

[1] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan

[2] Ajinomoto Co Inc, Cent Res Labs, Kawasaki Ku, Kawasaki, Kanagawa 2100801, Japan

[3] Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan

来源：

VACCINE | 2001年 / 20卷 / 5-6期

关键词：

HIV; neutralization antibody; HIV vaccine; Mycobacterium bovis BCG; rBCG;

D O I：

10.1016/S0264-410X(01)00398-X

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The recombinant Mycobacterium bovis BCG (rBCG) vector-based vaccine secreting the V3 principal neutralizing epitope of human immunodeficiency virus type 1 (HIV-1) Japanese strain was reported to induce both humoral and cellular immune responses effectively [Proc. Natl. Acad. Sci. USA. 92 (1995) 10693]. The antigen-secreting rBCG system was applied to the V3 epitope of clade E HIV-1 in this study. The V3 sequence of 19 amino acids (aa) and 15aa fused with mycobacterial alpha -antigen was not secreted while 12aa and 11aa sequences were successfully secreted from BCG cells. Serum IgG from guinea pig which was immunized with 12aa epitope-secreting recombinant BCG neutralized the WHO reference strain as well as primary field isolates of clade E virus. The serum IgG could also neutralize Thai B (clade B) strains which possessed a conserved GPGQ motif in their V3 sequences. These data suggest that the rBCG construct secreting the 12aa epitope is implicated in the development of a prophylactic vaccine in Thailand in which both clade E and B' viruses are prevalent. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：797 / 804

页数：8

共 40 条

[1] HUMORAL AND CELL-MEDIATED IMMUNE-RESPONSES TO LIVE RECOMBINANT BCG-HIV VACCINES [J].

ALDOVINI, A ;

YOUNG, RA .

NATURE, 1991, 351 (6326) :479-482

[2] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

Miller, J ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

SCIENCE, 2001, 292 (5514) :69-74

[3] Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].

Barouch, DH ;

Santra, S ;

Schmitz, JE ;

Kuroda, MJ ;

Fu, TM ;

Wagner, W ;

Bilska, M ;

Craiu, A ;

Zheng, XX ;

Krivulka, GR ;

Beaudry, K ;

Lifton, MA ;

Nickerson, CE ;

Trigona, WL ;

Punt, K ;

Freed, DC ;

Guan, LM ;

Dubey, S ;

Casimiro, D ;

Simon, A ;

Davies, ME ;

Chastain, M ;

Strom, TB ;

Gelman, RS ;

Montefiori, DC ;

Lewis, MG ;

Emini, EA ;

Shiver, JW ;

Letvin, NL .

SCIENCE, 2000, 290 (5491) :486-492

[4] Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand [J].

Berman, PW ;

Huang, W ;

Riddle, L ;

Gray, AM ;

Wrin, T ;

Vennari, J ;

Johnson, A ;

Klaussen, M ;

Prashad, H ;

Köhne, C ;

DeWit, C ;

Gregory, TJ .

VIROLOGY, 1999, 265 (01) :1-9

[5] Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients [J].

Burrer, R ;

Salmon-Ceron, D ;

Richert, S ;

Pancino, G ;

Spiridon, G ;

Haessig, S ;

Roques, V ;

Barre-Sinoussi, F ;

Aubertin, AM ;

Moog, C .

JOURNAL OF VIROLOGY, 2001, 75 (11) :5421-5424

[6] The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates [J].

Choe, H ;

Farzan, M ;

Sun, Y ;

Sullivan, N ;

Rollins, B ;

Ponath, PD ;

Wu, LJ ;

Mackay, CR ;

LaRosa, G ;

Newman, W ;

Gerard, N ;

Gerard, C ;

Sodroski, J .

CELL, 1996, 85 (07) :1135-1148

[7] HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5 [J].

Dragic, T ;

Litwin, V ;

Allaway, GP ;

Martin, SR ;

Huang, YX ;

Nagashima, KA ;

Cayanan, C ;

Maddon, PJ ;

Koup, RA ;

Moore, JP ;

Paxton, WA .

NATURE, 1996, 381 (6584) :667-673

[8] Characterization of V3 loop-Pseudomonas exotoxin chimeras -: Candidate vaccines for human immunodeficiency virus-1 [J].

Fitzgerald, DJ ;

Fryling, CM ;

McKee, ML ;

Vennari, JC ;

Wrin, T ;

Cromwell, MEM ;

Daugherty, AL ;

Mrsny, RJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9951-9958

[9]

Fomsgaard A, 1998, SCAND J IMMUNOL, V47, P289, DOI 10.1046/j.1365-3083.1998.00323.x

[10] Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain [J].

Girard, M ;

Yue, L ;

BarreSinoussi, F ;

VanderRyst, E ;

Meignier, B ;

Muchmore, E ;

Fultz, PN .

JOURNAL OF VIROLOGY, 1996, 70 (11) :8229-8233

← 1 2 3 4 →